Logotype for Avacta Group PLC

Avacta Group (AVCT) investor relations material

Avacta Group H1 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Avacta Group PLC
H1 2025 earnings summary30 Sep, 2025

Executive summary

  • Clinical programs are advancing, with ongoing Phase 1b expansion cohorts for AVA6000 (faridoxorubicin) showing encouraging initial activity and pivotal data expected at ESMO 2025 and late 2025.

  • AVA6103 (FAP-EXD) remains on track for first patient dosing in Q1 2026, with strong preclinical data showing durable responses in resistant animal models.

  • Strategic focus on partnerships, business development, and collaborations, including with Tempus AI, to support funding and clinical advancement.

  • Industry interest in the pre|CISION platform is increasing, with a pipeline update planned for October and new applications to be showcased.

  • Sale of Launch Diagnostics and Coris Diagnostics completed, supporting cash position.

Financial highlights

  • Cash and cash equivalents at period end were £12.65 million, down from £28.56 million year-over-year and £12.87 million at 2024 year-end.

  • Cash outflows from operations and working capital were £12.14 million for 1H25, compared to £12.6 million in 1H24.

  • Cash inflows from investing activities were £8.77 million, mainly from the sale of Launch Diagnostics.

  • Revenue from continuing operations was £0.06 million, unchanged year-over-year; discontinued operations revenue was £6.10 million.

  • Operating loss from continuing operations decreased to £14.18 million (H1 2024: £14.86 million).

Outlook and guidance

  • Cash runway extends into Q1 2026, with ongoing focus on strategic partnerships and funding levers.

  • Multiple pipeline updates and key data catalysts expected in late 2025, including ESMO 2025, salivary gland data, and initial AVA6103 clinical data in late 2026.

  • No further development of AVA6000 Phase 2 will occur without a partnership; maturing Phase 1B data expected to drive inflection points.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Avacta Group PLC is a biotechnology company specializing in the development of innovative diagnostic and therapeutic solutions. The company operates in two primary segments: diagnostics, where it develops rapid tests and reagents, and therapeutics, focusing on the development of precision oncology treatments. Avacta utilizes proprietary technologies, such as its Affimer platform, to create targeted therapies and diagnostic tools. The company is headquartered in Wetherby, United Kingdom, and its shares are listed on the AIM.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage